229 related articles for article (PubMed ID: 33468560)
1. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.
Wipke BT; Hoepner R; Strassburger-Krogias K; Thomas AM; Gianni D; Szak S; Brennan MS; Pistor M; Gold R; Chan A; Scannevin RH
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33468560
[TBL] [Abstract][Full Text] [Related]
2. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.
Brennan MS; Matos MF; Li B; Hronowski X; Gao B; Juhasz P; Rhodes KJ; Scannevin RH
PLoS One; 2015; 10(3):e0120254. PubMed ID: 25793262
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice.
Yao Y; Miao W; Liu Z; Han W; Shi K; Shen Y; Li H; Liu Q; Fu Y; Huang D; Shi FD
Transl Stroke Res; 2016 Dec; 7(6):535-547. PubMed ID: 27614618
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate for treating relapsing multiple sclerosis.
Sheremata W; Brown AD; Rammohan KW
Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the modification of Kelch-like ECH-associated protein 1 by different fumarates.
Qu L; Guo M; Zhang H; Chen X; Wei H; Jiang L; Li J; Chen Z; Dai S; Chen Y
Biochem Biophys Res Commun; 2022 May; 605():9-15. PubMed ID: 35306364
[TBL] [Abstract][Full Text] [Related]
7. Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
Haarmann A; Nehen M; Deiß A; Buttmann M
Int J Mol Sci; 2015 Aug; 16(8):19086-95. PubMed ID: 26287168
[TBL] [Abstract][Full Text] [Related]
8. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Wang Q; Chuikov S; Taitano S; Wu Q; Rastogi A; Tuck SJ; Corey JM; Lundy SK; Mao-Draayer Y
Int J Mol Sci; 2015 Jun; 16(6):13885-907. PubMed ID: 26090715
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.
Peng H; Li H; Sheehy A; Cullen P; Allaire N; Scannevin RH
J Neuroimmunol; 2016 Oct; 299():35-44. PubMed ID: 27725119
[TBL] [Abstract][Full Text] [Related]
11. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
[TBL] [Abstract][Full Text] [Related]
12. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
[TBL] [Abstract][Full Text] [Related]
13. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.
Goldman MD; Dwyer L; Coleman R; Sohn MW; Stuve O
PLoS One; 2020; 15(2):e0228617. PubMed ID: 32045436
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters.
Lee DH; Gold R; Linker RA
Int J Mol Sci; 2012; 13(9):11783-11803. PubMed ID: 23109883
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
19. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases.
Majkutewicz I
Eur J Pharmacol; 2022 Jul; 926():175025. PubMed ID: 35569547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
